What are the clinical uses, indications, and recommended dosage of melatonin?

Melatonin: Clinical Use, Purpose & Dosage

Melatonin is primarily indicated for circadian rhythm sleep-wake disorders (particularly delayed sleep-wake phase disorder) rather than chronic insomnia, where evidence is insufficient and it should not be first-line therapy.

Primary Clinical Indications

Circadian Rhythm Sleep-Wake Disorders (Strongest Evidence)

Delayed Sleep-Wake Phase Disorder (DSWPD) is where melatonin demonstrates the clearest efficacy 1. This is fundamentally different from insomnia—DSWPD involves a misaligned biological clock, not simply difficulty sleeping.

Adults with DSWPD:

• Dose: 5 mg
• Timing: Between 19:00-21:00 (7-9 PM), NOT at bedtime
• Duration: Minimum 28 days
• Evidence level: LOW quality, but clinically accepted 1

Critical timing principle: Melatonin works as a chronobiotic (circadian phase-shifter), not a sedative. Recent meta-analysis shows optimal administration is 3 hours before desired bedtime, not 30 minutes 2. The hormone advances your biological clock when given in the evening hours, which is why clock-time dosing (19:00-21:00) is more effective than "bedtime" dosing.

Children/Adolescents with DSWPD (No Comorbidities):

• Dose: 0.15 mg/kg (optimal dose from moderate-quality evidence)
  • Mean doses: 1.6 mg (0.05 mg/kg), 2.9 mg (0.1 mg/kg), or 4.4 mg (0.15 mg/kg)
• Timing: 1.5-2 hours before habitual bedtime
• Duration: Minimum 6 nights
• Evidence level: MODERATE 1

Children/Adolescents with DSWPD + Psychiatric Comorbidities (ADHD):

• Dose: Weight-based
  • 3 mg if <40 kg
  • 5 mg if >40 kg
• Timing: 18:00-19:00 (6-7 PM)
• Formulation: Fast-release specifically
• Duration: 4 weeks
• Evidence level: LOW 1

Chronic Insomnia (Limited Evidence)

The American Academy of Sleep Medicine found insufficient evidence to recommend melatonin for chronic insomnia 3. The American College of Physicians similarly concluded there was insufficient evidence to determine melatonin's efficacy in chronic insomnia 3.

However, for primary insomnia in adults over 55 years (where physiological melatonin production declines):

• Dose: 2 mg prolonged-release formulation only
• Timing: 1-2 hours before bedtime
• Duration: 3-12 weeks
• Evidence: Reduces sleep onset latency, improves sleep quality and morning alertness 4

Important distinction: This recommendation applies specifically to older adults with age-related melatonin deficiency, not younger adults with insomnia 3.

Dosing Principles Based on Recent Evidence

Dose-Response Relationship

A 2024 systematic review and dose-response meta-analysis found that melatonin's efficacy peaks at 4 mg/day for sleep onset latency and total sleep time 2. This challenges the common practice of using 2 mg doses.

Timing is More Critical Than Dose

Melatonin acts primarily as a chronobiotic, not a hypnotic 5, 6. Its effectiveness depends heavily on when it's given relative to:

1. The body's endogenous melatonin rhythm (dim light melatonin onset - DLMO)
2. The desired sleep time
3. Clock time (for circadian shifting)

Common error: Administering melatonin 30 minutes before bed like a sleeping pill. This timing is suboptimal for circadian phase advancement 2, 6.

Optimal timing:

• For circadian phase advancement: 3 hours before desired bedtime 2
• For hospitalized/elderly patients: Around 18:00 (6 PM), 1-2 hours before bedtime 6

Safety Profile

Melatonin demonstrates a favorable safety profile across age groups 4, 7:

• Mild side effects: drowsiness (28.8%), headache (25.1%) 8
• No serious adverse reactions documented
• No dependence or withdrawal symptoms, even at high doses 7
• Safe for long-term use in appropriate populations 4

Pediatric concerns: While no serious adverse effects have been reported, rigorous long-term safety data in children/adolescents are lacking. Informed consent from caregivers is essential 1.

Common Clinical Pitfalls

1. Misdiagnosis: Treating DSWPD as insomnia leads to treatment failure. DSWPD patients have delayed but normal sleep architecture once asleep; insomniacs have difficulty initiating/maintaining sleep regardless of timing 5.

2. Wrong timing: Using bedtime dosing (30 minutes before sleep) instead of earlier evening dosing (3 hours before or 18:00-21:00) 2, 5, 6.

3. Wrong formulation: Using immediate-release for insomnia instead of prolonged-release in elderly, or vice versa for DSWPD 1, 4.

4. Supraphysiological dosing without rationale: Many over-the-counter preparations contain 5-10 mg when physiological doses (0.3-1 mg) may suffice for some indications 5.

5. Lack of diagnostic rigor: Prescribing melatonin reflexively as a "natural sleep aid" without identifying the specific sleep disorder 5.

Formulation Considerations

• Fast/immediate-release: Preferred for DSWPD and circadian phase shifting 1
• Prolonged/sustained-release: Preferred for insomnia in elderly (mimics physiological secretion pattern) 4
• Over-the-counter variability: Substantial inconsistency in actual melatonin content versus labeled dose 5

Regulatory Status

Melatonin is NOT FDA-approved as a drug 6. It is regulated as a dietary supplement in the United States, leading to:

• Variable product quality and consistency
• Lack of standardized dosing guidelines
• Inconsistent formulations 5

This regulatory gap contributes to widespread misuse and misconceptions about proper administration 5.

Neurological Conditions (Emerging Evidence)

Alzheimer's Disease/Mild Cognitive Impairment:

• Dose: 2-10 mg
• Timing: As early as possible in disease course
• Duration: Long-term treatment
• Benefits: Improved sleep quality, regulated sleep/wake rhythm, possible cognitive benefit in MCI only (not moderate-severe AD)
• Synergy: Light therapy 12 hours before melatonin enhances effects 4

REM Sleep Behavior Disorder:

• Melatonin should be prescribed first-line (better side effect profile than clonazepam)
• Dose: Not specified in guidelines, but immediate-release formulation
• Timing: Shortly before bedtime
• Efficacy: Good effect on clinical symptoms and REM sleep without atonia 4

Parkinson's Disease:

• Insufficient evidence for specific recommendations beyond subjective sleep quality improvement 4

Epilepsy:

• Safe for regulating sleep/wake rhythm and treating insomnia
• More randomized controlled trials needed 4